Meeting Coverage:

American Society of Retina Specialists Annual Meeting

ASRS: 2022

Faricimab in Wet AMD After 2 Years

Show Description +

Arshad M. Khanani, MD, MA, shares late-breaking 2-year safety and efficacy data from the phase 3 trials for faricimab (Vabysmo, Genentech/Roche) in wet AMD.

Posted: 7/26/2022

Faricimab in Wet AMD After 2 Years

Arshad M. Khanani, MD, MA, shares late-breaking 2-year safety and efficacy data from the phase 3 trials for faricimab (Vabysmo, Genentech/Roche) in wet AMD.

Posted: 7/26/2022


Please log in to leave a comment.